Published in Oncotarget on February 01, 2012
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget (2014) 1.34
A gene expression profile test to resolve head & neck squamous versus lung squamous cancers. Diagn Pathol (2013) 0.80
Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget (2012) 0.78
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Multiple-laboratory comparison of microarray platforms. Nat Methods (2005) 11.74
The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Metastases to the female genital tract. Analysis of 325 cases. Cancer (1984) 2.32
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med (2005) 2.30
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology (2004) 1.90
Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol (2005) 1.69
Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab (2010) 1.57
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res (2005) 1.52
Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol (2010) 1.51
Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics (2009) 1.47
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer (2008) 1.44
Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn (2010) 1.27
Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med (2008) 1.14
The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium. Obstet Gynecol Int (2009) 1.05
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res (2005) 1.02
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol (2006) 1.02
Wnt/Β-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget (2010) 1.01
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res (2006) 0.92
Netrin-1 overexpression is predictive of ovarian malignancies. Oncotarget (2011) 0.91
HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer (2009) 0.89
Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells. Oncotarget (2011) 0.85
Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. Prostate (2009) 0.84
Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol (1993) 0.82
Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol (2001) 0.81
Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer (2006) 0.77
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol (2009) 2.40
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol (2008) 2.11
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol (2003) 2.07
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer (2008) 1.92
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res (2003) 1.81
Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol (2008) 1.79
Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol (2008) 1.74
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64
Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke (2009) 1.61
Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation (2004) 1.53
Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn (2007) 1.44
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst (2004) 1.42
To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol (2009) 1.38
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol (2008) 1.36
Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol (2009) 1.32
Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol (2010) 1.31
Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer (2008) 1.30
Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn (2010) 1.27
SynDB: a Synapse protein DataBase based on synapse ontology. Nucleic Acids Res (2006) 1.25
Management of melanomas of the female genital tract. Curr Opin Oncol (2008) 1.25
Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation (2005) 1.24
Characteristics of success in mentoring and research productivity - a case-control study of academic centers. Gynecol Oncol (2012) 1.23
Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol (2007) 1.18
Bats respond to polarity of a magnetic field. Proc Biol Sci (2007) 1.17
Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol (2006) 1.16
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest (2002) 1.13
A comparability study of the emerging protein array platforms with established ELISA procedures. J Immunol Methods (2005) 1.13
The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol (2007) 1.13
PRDM9 binding organizes hotspot nucleosomes and limits Holliday junction migration. Genome Res (2014) 1.12
Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer (2007) 1.11
Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol (2005) 1.10
Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys (2008) 1.09
Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol (2011) 1.09
DNA binding specificities of the long zinc-finger recombination protein PRDM9. Genome Biol (2013) 1.08
Reservoir boundaries in Brownian dynamics simulations of ion channels. Biophys J (2002) 1.08
Cervical cancer. J Natl Compr Canc Netw (2010) 1.07
Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol (2010) 1.06
Coordinated expression domains in mammalian genomes. PLoS One (2010) 1.05
RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood (2011) 1.04
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res (2005) 1.04
Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet Gynecol (2015) 1.04
High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer (2003) 1.03
Radical resection in signet ring carcinoma of the ampulla of Vater: report of an 11-year survivor. Am Surg (2006) 1.03
Cross-validation pitfalls when selecting and assessing regression and classification models. J Cheminform (2014) 1.02
Mesonephric adenocarcinoma of the cervix: a case report and review of the literature. Gynecol Oncol (2006) 1.01
Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol Heart Circ Physiol (2007) 1.01
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol (2009) 1.00
Unique vascular phenotypes following over-expression of individual VEGFA isoforms from the developing lens. Angiogenesis (2006) 0.99
Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol (2007) 0.99
Structural changes to electronic gaming machines as effective harm minimization strategies for non-problem and problem gamblers. J Gambl Stud (2005) 0.98
Controlling wound bioburden with a novel silver-containing Hydrofiber dressing. Wound Repair Regen (2004) 0.98
Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol (2007) 0.96
A pilot study of exercise training in adult patients with repaired tetralogy of Fallot. Can J Cardiol (2003) 0.96
Patterns of recombination activity on mouse chromosome 11 revealed by high resolution mapping. PLoS One (2010) 0.96
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol (2006) 0.95
Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys (2005) 0.95
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys (2013) 0.94
Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2009) 0.93
Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 0.93
The management of small-cell carcinomas of the gynecologic tract. Curr Opin Oncol (2012) 0.91
Identification of tissue of origin in body fluid specimens using a gene expression microarray assay. Cancer Cytopathol (2011) 0.91
A comparative study of the structure of human and murine greater omentum. Anat Embryol (Berl) (2005) 0.91
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis. Oncologist (2014) 0.91
The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol (2006) 0.90
Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol (2008) 0.89
Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol (2008) 0.89
Incidental testicular irradiation from prostate IMRT: it all adds up. Int J Radiat Oncol Biol Phys (2009) 0.88
The value of surgery for retroperitoneal sarcoma. Sarcoma (2009) 0.88
Antimicrobial properties of silver-containing wound dressings: a microcalorimetric study. Int J Pharm (2003) 0.88
The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol (2006) 0.87
Testicular dose from prostate cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys (2009) 0.87
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res (2005) 0.87
Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys (2007) 0.86
Osteomyelitis secondary to trauma involving the proximal end of the radius in horses: five cases (1987-2001). J Am Vet Med Assoc (2003) 0.86
An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecol Oncol (2011) 0.86
Unique patterns of metastases in common and rare types of malignancy. J Surg Oncol (2011) 0.86
Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol (2007) 0.86
A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol (2013) 0.85
The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses. Phase 1: use of a potent agonist and a potent antagonist to test the standardized protocol. Environ Health Perspect (2006) 0.85
Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med (2012) 0.85
Shear-stress preconditioning and tissue-engineering-based paradigms for generating arterial substitutes. Biotechnol Appl Biochem (2004) 0.85
Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol (2007) 0.85
A multi-laboratory evaluation of a clinically-validated incurred quality control material for analysis of allergens in food. Food Chem (2013) 0.84
Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer. Diagn Pathol (2012) 0.84
Accuracy of conventional radiography and computed tomography in predicting implant position in relation to the vertebral canal in dogs. Vet Surg (2010) 0.84
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Res Treat (2014) 0.84
Cervical cancer. J Natl Compr Canc Netw (2008) 0.83
An economic analysis of robotic versus laparoscopic surgery for endometrial cancer: costs, charges and reimbursements to hospitals and professionals. Gynecol Oncol (2011) 0.83
The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses: phase 2 dose-response studies. Environ Health Perspect (2007) 0.82
Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. Int J Radiat Oncol Biol Phys (2008) 0.82
Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer. J Surg Oncol (2012) 0.81
Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation. PLoS One (2012) 0.81
Automatic liver contouring for radiotherapy treatment planning. Phys Med Biol (2015) 0.81